LensGen(R) Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors
IRVINE, Calif., Aug. 20, 2020 -- (Healthcare Sales & Marketing Network) -- LensGen, Inc., an ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces t... Devices, Ophthalmology, Venture Capital, Personnel LensGen, Juvene, intraocular lens, presbyopia, cataract
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cataracts | Marketing | Medical Devices | Opthalmology | Pharmaceuticals | Venture Capital